HANSAE YES24 HOLDINGS CO., LTD

(A016450)
  Bericht
Schlusskurs Korea Stock Exchange  -  12.08.2022
5860.00 KRW   +0.69%
16.05.Hansae Yes24 Holdings Co., Ltd. meldet Ergebnis für das erste Quartal zum 31. März 2022
CI
21.03.Hansae Yes24 Holdings Co., Ltd. meldet Ergebnis für das Geschäftsjahr zum 31. Dezember 2021
CI
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzen 
ÜbersichtAlle NewsAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über HANSAE YES24 HOLDINGS CO., LTD
10.08.European Society for Organ Transplantation's (ESOT) guidelines for desensitization trea..
19.07.Hansa Biopharma half year report 2022
18.07.Hansa Biopharma announces $70 million non-dilutive product finance transaction with Nov..
11.07.Hansa Biopharma announces first patient treated in the post-authorization efficacy stud..
30.06.Increase of the number of votes in Hansa Biopharma
30.06.Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
30.06.Hansa Biopharma to host conference call to provide half year results for January-June 2..
16.06.NICE recommends use of Hansa Biopharma's Idefirix® (imlifidase) as desensitization trea..
30.05.HANSA BIOPHARMA : Notice to Annual General Meeting
30.05.The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the ..
23.05.Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated r..
16.05.Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the First Quarter Ended Mar..
13.05.Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix..
21.04.Hansa Biopharma interim report January - March 2022
20.04.Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idef..
19.04.Hansa Biopharma announces U.S. FDA acceptance of Investigational New Drug (IND) applica..
07.04.Hansa Biopharma publishes Annual Report 2021
28.03.Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefi..
21.03.Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Full Year Ended Decembe..
15.03.Hansa Biopharma and German payer head association agree on reimbursement price for Idef..
08.03.Key data demonstrating the potential of Hansa Biopharma's imlifidase to significantly a..
25.02.Hansa Biopharma announces positive early access decision by French Haute Autorité de Sa..
03.02.Hansa Biopharma year-end report 2021
20.01.Hansa Biopharma to host conference call to provide Year-End report for 2021 and Busines..
09.01.Hansa Biopharma provides business update including certain key financials
03.01.Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase..
2021Increase of the number of shares and votes in Hansa Biopharma AB
2021Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of i..
2021HANSA BIOPHARMA : Issue and repurchase of class C shares for incentive programs
2021Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership..
2021Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Third Quarter and Nine ..
2021Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Baseme..
2021Hansa Biopharma Nomination Committee formed
2021Hansa Biopharma announces it has confidentially submitted a draft registration statemen..
2021HANSA BIOPHARMA : interim report Jan-Sept 2021
2021HANSA BIOPHARMA : to host conference call to provide interim results for January-September..
2021HANSAE YES24 HOLDINGS CO., LTD(KOSE : A016450) added to S&P Global BMI Index
2021HANSA BIOPHARMA : presented new data on imlifidase at the European Society for Organ Trans..
2021HANSA BIOPHARMA : announces participation in Fall investor conferences and provides update..
2021HANSA BIOPHARMA : achieves Great Place to Work certification for second consecutive year
2021HANSA BIOPHARMA : announces reimbursement in the Netherlands of Idefirix (imlifidase) as d..
2021HANSA BIOPHARMA : interim report Jan-June 2021
2021HANSA BIOPHARMA : announces long term follow-up data demonstrating 3-year graft survival o..
2021HANSA BIOPHARMA : to host conference call to provide interim results for first half 2021 a..
2021HANSA BIOPHARMA : announces decision by Swedish New Therapies Council to recommend use of ..
2021HANSA BIOPHARMA : announces study design for a US randomized, controlled trial of imlifida..
2021HANSA BIOPHARMA : Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
2021HANSA BIOPHARMA : interim report Jan-Mar 2021
2021HANSA BIOPHARMA : to host conference call to provide interim results from Q1 2021 and Busi..
2021HANSA BIOPHARMA : Notice to Annual General Meeting
2021HANSA BIOPHARMA : publishes Annual Report 2020
2021HANSA BIOPHARMA : enters preclinical research collaboration with argenx
2021HANSA BIOPHARMA : appoints Dr. Magnus Korsgren as Head of Research & Development
2021HANSA BIOPHARMA : year-end report Jan-Dec 2020
2021HANSA BIOPHARMA : to host conference call to provide Year-End report 2020 and Business Upd..
2020HANSA BIOPHARMA :  Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conferen..
2020KakaoBank of Korea Corp. cancelled the acquisition of 5.1% stake in Hansae Yes24 Holdin..
2020HANSA BIOPHARMA : Nomination Committee formed
2020Hansa Biopharma interim report Jan-Sep 2020
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-initiated ..
2020HANSAE YES24 HOLDINGS CO., LTD(KOSE : A016450) dropped from S&P Global BMI Index
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29, 2020 in C..
2020HANSA BIOPHARMA : certified as a Great Place to Work
2020HANSA BIOPHARMA : provides updated guidance on its clinical programs
2020HANSA BIOPHARMA : announces participation in Fall conferences and an updated financial cal..
2020HANSA BIOPHARMA PUBL : announces increase in number of shares and votes
2020HANSA BIOPHARMA PUBL : expands the leadership team with the appointment of Katja Margell a..
2020Hansa Biopharma interim report Jan-Jun 2020
2020HANSA BIOPHARMA PUBL : announces successful completion of SEK 1.1bn (USD 121m) placing of ..
2020HANSA BIOPHARMA PUBL : announces intention to carry out a placing of new ordinary shares
2020Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and ..
2020HANSA BIOPHARMA PUBL : to host conference call to provide interim results for the first ha..
2020HANSA BIOPHARMA PUBL : receives positive CHMP opinion for Idefirix (imlifidase) for kidney..
2020HANSA BIOPHARMA PUBL : Bulletin from the Annual General Meeting in Hansa Biopharma AB (pub..
2020HANSA BIOPHARMA PUBL : appoints Achim Kaufhold as CMO to support the expansion outside tra..
1  2Weiter
Anstehende Termine für HANSAE YES24 HOLDINGS CO., LTD